Executive Summary
NASA's $109.2M delivery order to Caltech for JPL FFRDC operations and EMIT project, with $90.3M outlayed, signals stable federal space R&D funding through 2028 but neutral equity impact due to nonprofit recipient. Unexercised $16.2M options offer modest upside potential amid task order dependence. No direct investment catalysts; monitor for sector spillovers in aerospace R&D.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior High-Value Federal Grants ($5M+) digest from March 15, 2026.
Risk Flags (1)
- Execution [MEDIUM RISK]▼
Long 10-year performance period to 2028-09-30 with full obligation dependent on future NASA task orders.
Opportunities (1)
- ◆
$16.2M unexercised options to reach $125.4M ceiling, plus ongoing JPL FFRDC role enabling additional NASA task orders through 2028.
Sector Themes (1)
- ◆
High-value non-competed award under NAICS 541715 for EMIT mineral dust investigation and JPL operations highlights sustained federal commitment.
Watch List (1)
- 👁
{"entity"=>"Caltech/JPL Task Orders", "reason"=>"Core to realizing full $125.4M potential through 2028 amid $90.3M outlays.", "trigger"=>"New awards or option exercises signaling expanded scope."}
Get daily alerts with 1 risk alerts, 1 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: High-Value Federal Grants ($5M+)
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals